Welcome to Money, Sky News' consumer and financial news hub. Today: house asking prices have reached a record high; what it's ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

The U.S. Federal Trade Commission is concerned about the potential sale or transfer of Americans' personal information by 23andMe ME.O ancestry testing company which recently filed for ...

Detailed price information for 23Andme Holding Co. (ME-Q) from The Globe and Mail including charting and trades.

Competitors like AncestryDNA and MyHeritage, both vying for customers in the at-home genetics and health space ... used by 23andMe, drawn from customer at-home testing kits, poses risks of ...

Founded in 2006, 23andMe is a direct-to-consumer genetics company offering at-home DNA testing kits to help users explore their ancestry, health traits, and genetic risks. In recent years ... trying ...

The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

Privacy experts are concerned about the risk of “genetic discrimination” after 23andMe, which offered a direct-to-consumer genetic testing service, filed for ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...

23andMe, the company whose mail-in self-testing ... there's no legal obligation to ensure customer privacy under another owner. The risks, Caplan said, is that the data could be used in ways ...